Cargando…

Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting SYT13 to Treat Peritoneal Metastasis of Gastric Cancer

Patients with peritoneal metastasis of gastric cancer have dismal prognosis, mainly because of inefficient systemic delivery of drugs to peritoneal tumors. We aimed to develop an intraperitoneal treatment strategy using amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides (ASOs) tar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanda, Mitsuro, Kasahara, Yuuya, Shimizu, Dai, Miwa, Takashi, Umeda, Shinichi, Sawaki, Koichi, Nakamura, Shunsuke, Kodera, Yasuhiro, Obika, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644579/ https://www.ncbi.nlm.nih.gov/pubmed/33230476 http://dx.doi.org/10.1016/j.omtn.2020.10.001

Ejemplares similares

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease
por: Uehara, Takuya, et al.
Publicado: (2019)

Design and In Vitro Evaluation of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, and Guanidine-Bridged Nucleic Acids
por: Shimo, Takenori, et al.
Publicado: (2021)

Base-modified aptamers obtained by cell-internalization SELEX facilitate cellular uptake of an antisense oligonucleotide
por: Tanaka, Keisuke, et al.
Publicado: (2020)

Hydrogen peroxide-triggered gene silencing in mammalian cells through boronated antisense oligonucleotides
por: Mori, Shohei, et al.
Publicado: (2017)

An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells
por: Yoshida, Misa, et al.
Publicado: (2023)

Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides
por: Yoshida, Tokuyuki, et al.
Publicado: (2022)

Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides
por: Wada, Fumito, et al.
Publicado: (2021)

A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
por: Shimojo, Masahito, et al.
Publicado: (2019)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer
por: Kanda, Mitsuro, et al.
Publicado: (2020)

Hybrid-Type SELEX for the Selection of Artificial Nucleic Acid Aptamers Exhibiting Cell Internalization Activity
por: Uemachi, Hiro, et al.
Publicado: (2021)

Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53–Bcl-2 intrinsic apoptosis pathway
por: Miwa, Takashi, et al.
Publicado: (2021)

2′-O-Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping
por: Lee, Tomoko, et al.
Publicado: (2017)

Synthesis and properties of oligonucleotides modified with an N-methylguanidine-bridged nucleic acid (GuNA[Me]) bearing adenine, guanine, or 5-methylcytosine nucleobases
por: Horie, Naohiro, et al.
Publicado: (2021)

Synthesis and Evaluation of Artificial Nucleic Acid Bearing an Oxanorbornane Scaffold
por: Komine, Hibiki, et al.
Publicado: (2020)

Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides
por: Burdick, Andrew D., et al.
Publicado: (2014)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Mechanism of the extremely high duplex-forming ability of oligonucleotides modified with N-tert-butylguanidine- or N-tert-butyl-N′- methylguanidine-bridged nucleic acids
por: Yamaguchi, Takao, et al.
Publicado: (2023)

Cell-permeable peptide nucleic acid antisense oligonucleotide platform targeting human betacoronaviruses
por: Park, Soree, et al.
Publicado: (2023)

Study on Suitability of KOD DNA Polymerase for Enzymatic Production of Artificial Nucleic Acids Using Base/Sugar Modified Nucleoside Triphosphates
por: Kuwahara, Masayasu, et al.
Publicado: (2010)

Evaluation of off‐target effects of gapmer antisense oligonucleotides using human cells
por: Yoshida, Tokuyuki, et al.
Publicado: (2019)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
por: Stein, C. A., et al.
Publicado: (2010)

Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides
por: Uemura, Yasunori, et al.
Publicado: (2019)

Synthesis and biophysical properties of carbamate-locked nucleic acid (LNA) oligonucleotides with potential antisense applications
por: Thorpe, Cameron, et al.
Publicado: (2019)

Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties
por: Papargyri, Natalia, et al.
Publicado: (2019)

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies
por: Easton, Amy, et al.
Publicado: (2022)

A bridged nucleic acid, 2′,4′-BNA(COC): synthesis of fully modified oligonucleotides bearing thymine, 5-methylcytosine, adenine and guanine 2′,4′-BNA(COC) monomers and RNA-selective nucleic-acid recognition
por: Mitsuoka, Yasunori, et al.
Publicado: (2009)

Superior Silencing by 2′,4′-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2′,4′-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2012)

Artificial Specific Binders Directly Recovered from Chemically Modified Nucleic Acid Libraries
por: Kasahara, Yuuya, et al.
Publicado: (2012)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Interface Symbiotic Membrane Formation in Root Nodules of Medicago truncatula: the Role of Synaptotagmins MtSyt1, MtSyt2 and MtSyt3
por: Gavrin, Aleksandr, et al.
Publicado: (2017)

Syt-12 for spontaneous release
por: LeBrasseur, Nicole
Publicado: (2007)

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2012)

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
por: Kasuya, Takeshi, et al.
Publicado: (2016)

Alpha-l-Locked Nucleic Acid-Modified Antisense Oligonucleotides Induce Efficient Splice Modulation In Vitro
por: Raguraman, Prithi, et al.
Publicado: (2020)

Multi-targeted Antisense Oligonucleotide Delivery by a Framework Nucleic Acid for Inhibiting Biofilm Formation and Virulence
por: Zhang, Yuxin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nv86j7emb2sdqe7r0mcc2nfota